TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, ... TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on mature B-lymphocytes. It is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor. Show more
NEW YORK, Nov. 29, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Companyβs Chairman and Chief Executive Officer, will participate in...
NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX),Β today announced it ranked number one on the Deloitte Technology Fast 500β’, a ranking of the 500 fastest-growing...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 1.485 | 4.83477128439 | 30.715 | 35.03 | 30.41 | 2562218 | 32.66461987 | CS |
4 | -2.085 | -6.08137669535 | 34.285 | 36.84 | 30.41 | 2164116 | 33.3323396 | CS |
12 | 8.63 | 36.614340263 | 23.57 | 36.84 | 21.16 | 2964044 | 28.47350832 | CS |
26 | 15.42 | 91.89511323 | 16.78 | 36.84 | 16.65 | 3307283 | 24.64920077 | CS |
52 | 13.61 | 73.2114039806 | 18.59 | 36.84 | 12.84 | 3610035 | 20.14218055 | CS |
156 | 14.43 | 81.2042768711 | 17.77 | 36.84 | 3.48 | 3853489 | 14.90836831 | CS |
260 | 22.35 | 226.903553299 | 9.85 | 56.74 | 3.48 | 3009979 | 17.77945024 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.